Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Viatris announced six data presentations at the 2026 ACOG Annual Clinical & Scientific Meeting highlighting positive results from the Phase 3 study of its investigational low-dose estrogen weekly patch (MR-100A-01). The data covers contraceptive efficacy, safety, adhesion performance, and pharmacokinetics, reinforcing the favorable profile noted in the NDA submission.
Key figures
- Drug Name
- MR-100A-01 (low-dose estrogen combined hormonal contraceptive weekly patch)
- Phase Of Trial
- Phase 3
- Trial Id
- NCT05139121
- Pdufa Date
- July 30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.